ENGINEERING MEDICINES TO IMPROVE PATIENT CARE Investors News Releases Year None20232022202120202019201820172016 September 25, 2023 Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 6, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society June 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
Year None20232022202120202019201820172016 September 25, 2023 Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) July 6, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society June 5, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 26
September 7, 2023 Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
August 8, 2023 Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 4, 2023 Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 10, 2023 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
June 13, 2023 Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
May 9, 2023 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections